

Endocrine Abstracts

September 2020 Volume 70
ISSN 1479-6848 (online)

22nd European Congress of
Endocrinology

5-9 September 2020, European Society of Endocrinology

eECE 2020
22nd European Congress of Endocrinology



published by
bioscientifica

Online version available at
www.endocrine-abstracts.org



22nd European Congress of Endocrinology 5-9 September 2020, European Society of Endocrinology

EDITORS

Abstracts were marked by the Abstract Marking Panel and selected by the Programme Organising Committee

e-ECE 2020 Mini-Programme Organising Committee

Andrea Giustina (Italy), **ESE President**
Martin Reincke (Germany), **ESE President-Elect**
Bulent Yildiz (Turkey), **ESE Treasurer (until May 2020)**
Riccarda Granata (Italy), **ESE Congress Committee Chair**

Attila Balázs Patócs (Hungary), **2020 POC Co-Chair**
Jens Otto Lunde Jørgensen (Denmark), **2020 POC Co-Chair**
Daniela Cota (France), **2021 POC Co-Chair**
Lars Rejnmark (Denmark), **2021 POC Co-Chair**

Ljiljana Marina (Serbia), **EYES Chair**
Manel Puig Domingo (Spain), **2020 POC Member**
Mónica Marazuela (Spain), **ESE Secretary**

Programme Organising Committee

Riccarda Granata (Italy), **ESE Congress Committee Chair**
Jens Otto Lunde Jørgensen (Denmark), **Clinical Co-Chair**
Attila Balázs Patócs (Hungary), **Basic Science Co-Chair**
Michal Kršek (Czech Republic), **Local Organising Committee Chair**
Zhanna Belaya (Russian Federation)
Nienke Biermasz (The Netherlands)
Jens Bollersev (Norway)

Daniela Cota (France)
Ashley Grossman (UK)
Csilla Krausz (Italy)
Madalina Musat (Romania)
Uberto Pagotto (Italy)
Agnieszka Piekliko-Witkowska (Poland)
Vincent Prevot (France)
Manel Puig-Domingo (Spain)

Lars Rejnmark (Denmark)
Mark Sherlock (Ireland)
Marilyn Theodoropoulou (Germany)
Pierre Val (France)
AJ van der Lely (The Netherlands)
Wim van Hul (Belgium)
Greisa Vila (Austria)
Maria Chiara Zatelli (Italy)

Ex Officio Members

Andrea Giustina (Italy), **ESE President**
Martin Reincke (Germany), **ESE President-Elect**
Bulent Yildiz (Turkey), **ESE Treasurer (until May 2020)**
Wiebke Arlt (UK), **Editor in Chief, European Journal of Endocrinology**

Josef Köhrle (Germany), **Editor in Chief, Endocrine Connections**
Felix Beuschlein (Switzerland), **ESE Clinical Committee Chair**
Robin Peeters (Switzerland), **ESE Science Committee Chair**
Riccarda Granata (Italy), **ESE Congress Committee Chair**

Marek Ruchala (Poland), **ECAS Representative**
Mehul Dattani (UK) (Switzerland), **ESPE Representative**
Luis Cardoso (Portugal), **EYES Representative**

Abstract Marking Panel

Marker Name	Country	L Czupryniak	Poland	D Grigorie	Romania	M Krsek	Czech Republic	N Papanas	Greece	E Shestakova	Russia
M Alevizaki	Greece	J Dahlgren	Sweden	P Groop	Finland	A Kurylowicz	Poland	A Patócs	Hungary	M Shestakova	Russia
K Amrein	Austria	P Dahlgvist	Sweden	A Grossman	UK	E Lalli	France	R Peeters	The Netherlands	M Simoni	Italy
C Andoniadu	UK	C Daoussi	UK	L Groussin	France	B Langdahl	Denmark	S Pekic	Serbia	J Skrbha	Austria
G Assié	France	M Dattani	UK	G Gruden	Italy	B Lapauw	Belgium	N Pellegata	Germany	P Soares	Portugal
S Babajko	France	C Dayan	UK	L Guasti	UK	J Laven	The Netherlands	L Perez-Rivas	Germany	A Solini	Italy
C Badiu	Romania	J de Castro	Portugal	M Haluzik	Czech Republic	G Lavery	UK	H Perrild	Denmark	A Spada	Italy
A Baranowska-Bik	Poland	W de Herder	The Netherlands	R Hampl	Czech Republic	L Laviola	Italy	L Persani	Italy	J Spranger	Germany
A Barlier	France	E de Koning	The Netherlands	V Hána	Czech Republic	I Lazurova	Slovakia	G Perseghin	Italy	A Spyrgioulou	Germany
K Basham	USA	W Dhillon	UK	F Hannan	UK	H Lefebvre	France	M Petakov	Serbia	G Stalla	Germany
A Beckers	Belgium	G Di Dalmazi	Germany	A Heck	Norway	J Leger	France	A Piekliko-Witkowska	Poland	E Stener-Victorin	Sweden
P Beck-Peccoz	Italy	E Diamanti-Kandarakis	Greece	M Heikkinen	Finland	T Links	The Netherlands	V Pirags	Latvia	C Strasburger	Germany
Z Belaya	Russia	C Dieguez	Spain	A Hoellich	Germany	P Lips	The Netherlands	C Poiana	Romania	C Stratakis	USA
J Bertherat	France	E Dirinck	Belgium	L Holland	The Netherlands	S Llahana	UK	R Poladian	Lebanon	A Tabarin	France
M Bidlingmaier	Germany	M Donath	Switzerland	A Hubalewska-Dydejczyk	Poland	A Luger	Austria	S Polyzos	Greece	T Tankova	Bulgaria
N Biermasz	The Netherlands	J Drouin	Canada	I Huhtaniemi	UK	S Lund	Denmark	P Poplawski	Poland	M Tena-Sempere	Spain
W Bik	Poland	L Duntas	Greece	E Husebye	Norway	R Luque	Spain	V Popović	Serbia	N Tentolouris	Greece
K Birkeland	Norway	A Dwyer	USA	P Igaz	Hungary	D Macut	Serbia	M Porta	Italy	M Terzolo	Italy
K Boelaert	UK	G Eisenhofer	Germany	I Ilavskaya	Russia	D Maiter	France	M Poutanen	Finland	M Theodoropoulou	Germany
J Boguslawska	Poland	V Elia	Romania	E Isenovic	Serbia	E Mamedova	Russia	D Power	Portugal	C Thompson	Ireland
J Bøllerslev	Norway	F Fallo	Italy	M Jaffrain-Rea	Italy	M Mannelli	Italy	M Puig Domingo	Spain	H Timmers	The Netherlands
R Bouillon	Belgium	M Fassnacht	Germany	B Jarzab	Poland	E Mannucci	Italy	C Quarta	France	M Toth	Hungary
M Brandt	Italy	J Favier	France	K Jazdzewski	Poland	F Mantero	Italy	S Radian	Romania	P Touraine	France
D Branisteanu	Romania	R Feelders	The Netherlands	N Jessen	Denmark	G Mantovani	ITALY	O Ragnarsson	Sweden	R Trifanescu	Romania
K Briot	France	U Feldt-Rasmussen	Denmark	D Jezova	Slovakia	M Marazuela	Spain	N Rahman	Finland	A Tsapas	Greece
T Brue	France	F Fernandes Rosa	France	G Johansson	Sweden	L Marina	Serbia	E Rajpert-De Meyts	Denmark	ETsoudi	Germany
G Brunetti	Italy	S Fica	Romania	A Jørgensen	Norway	N Matikainen	Finland	M Rauner	Germany	M Tzanela	Greece
C Buchanan	UK	E Fliers	The Netherlands	J Jørgensen	Denmark	C McCabe	UK	G Raverot	France	E Valassi	Spain
P Burman	Sweden	S Franks	UK	U Kaiser	USA	O Meijer	The Netherlands	M Reincke	Germany	G Valk	The Netherlands
H Butz	Hungary	W Fraser	UK	G Kaltsas	Greece	L Metherell	UK	L Rejnmark	Denmark	E van den Akker	The Netherlands
S Cannavo	Italy	J Frystyk	Denmark	C Kanaka-Gantenbein	Greece	D Miljic	Serbia	S Rice	UK	erlands	
J Cap	Czech Republic	L Fugazzola	Italy	G Kanakis	Greece	J Mittag	Germany	M Robledo	Spain	A van der Lely	The Netherlands
C Capatina	Romania	C Fuà	Germany	T Kararup Hansen	Denmark	N Møller	Denmark	P Rodien	France	J van Eck	The Netherlands
M Caprio	Italy	F Gabalec	Czech Republic	D Karasek	Czech Republic	L Morin-Papunen	Finland	H Romijn	The Netherlands	W van Hul	Belgium
P Caron	France	S Gaberšček	Slovenia	N Karavitaki	UK	A Mukherjee	UK	C Ronchi	Italy	M Vantyghem	France
J Castaño	Spain	M Gabete	Spain	A Karlsson	Sweden	M Musat	Romania	R Ross	UK	G Vila	Austria
H Cederberg-		R Gärtner	Germany	S Kaser	Austria	E Nagy	Hungary	R Roussel	France	E Visser	The Netherlands
Tamminen	Finland	B Gatta Cherifi	France	D Kastelan	Croatia	S Neggers	The Netherlands	N Rucci	Italy	J Visser	The Netherlands
O Chabre	France	L Gennari	Italy	J Kaufman	Belgium	J Newell-Price	UK	M Ruchala	Poland	V Volke	Estonia
P Chanson	France	M Gheorghiu	Romania	M Keil	USA	N Nicolaidis	Greece	E Rutten	Belgium	J Widimsky	Czech Republic
K Chatterjee	UK	I Gherlan	Romania	F Kelestimur	Turkey	D Niculescu	Romania	S Sanack	Turkey	W Wiersinga	The Netherlands
N Cherradi	France	P Giacobini	France	R Kineman	USA	M Niedziela	Poland	D Santi	Greece	I Wilkinson	UK
M Chiara Zatelli	Italy	F Giorgino	Italy	T Kocjan	Slovenia	R Nogueiras	Spain	P Saunders	UK	T Williams	Germany
F Chiarelli	Italy	A Giustina	Italy	J Kopchick	USA	B Obermayer-Pietsch	Austria	C Schalin-Jäntti	Finland	S Wudy	Germany
J Chowen	Spain	M Godlewska	Poland	M Korbonits	UK	C Olareus	Norway	S Schmid	Germany	P Yeoh	UK
S Christin-Maitre	France	J Gomez-Ambrosi	Spain	B Kos-Kudla	Poland	P Oliveira	Portugal	J Schopohl	Germany	B Yildiz	Turkey
M Cohen-Solal	France	D Goulis	Greece	C Krausz	Italy	D Olsson	Sweden	D Schulte	Germany	M Zarkovic	Serbia
D Cota	France	R Granata	Italy	M Kroiss	Germany	K Øystese	Norway	P Schwarz	Denmark	M Zennaro	France
D Cuthbertson	UK	C Gravholt	Denmark	N Krone	UK	U Pagotto	Italy	M Sherlock	Ireland		

CONTENTS

e-ECE 2020

22nd European Congress of Endocrinology

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The Geoffrey Harris Prize Lecture	AP1
The <i>European Journal of Endocrinology</i> Prize Lecture	AP2
European Hormone Medal Lecture	AP3
Clinical Endocrinology Trust Lecture	AP4

PLENARY LECTURES

Exercise as medicine – a translational perspective	PL1
Glucocorticoids in cancer: a new paradigm	PL2
Harnessing the microbiome in metabolic disease	PL3
Mechanisms for SARS-CoV-2 cell entry	PL4
Maternal thyroid hormone and child brain development	PL5
It takes thyroid hormone to make sense	PL6
Effects of EDCs on neuro-endocrine systems and behaviour	PL7

SYMPOSIA

New horizons in pheochromocytoma and paraganglioma	S1.1–S1.3
Osteoporosis and fracture prediction	S2.1–S2.3
Controversial issues in bariatric surgery	S3.1–S3.3
Unveiling signatures in pituitary neuroendocrine tumours	S4.1–S4.3
Hyperthyroidism across the lifespan	S5.1–S5.3
Adrenocortical carcinoma	S6.1–S6.3
Endocrine disruptors, just a hype or not?	S7.1–S7.3
PCOS: from Genetics to Treatment	S8.1–S8.3

COVID-19 SESSION

Endocrine targets related to COVID infection	CS1.1
Managing the Cytokine storm.	CS1.2
How strong is obesity as a risk factor for COVID-19 patients	CS1.3

ORAL COMMUNICATIONS

Adrenal and Cardiovascular Endocrinology	OC1.1–OC1.7
Bone and Calcium	OC2.1–OC2.7
Diabetes, Obesity, Metabolism and Nutrition	OC3.1–OC3.7
Pituitary and Neuroendocrinology	OC4.1–OC4.7
Thyroid	OC5.1–OC5.7
Hot Topics (including COVID -19)	OC6.1–OC6.7
Endocrine-related Cancer	OC7.1–OC7.7
Environmental Endocrinology	OC8.1–OC8.6
Reproductive and Developmental Endocrinology	OC9.1–OC9.7
Young Investigators	YI1–YI12

AUDIO EPOSTER PRESENTATIONS

Adrenal and Cardiovascular Endocrinology	AEP1–AEP121
Bone and Calcium	AEP122–AEP242
Diabetes, Obesity, Metabolism and Nutrition	AEP243–AEP527
Endocrine-related Cancer	AEP528–AEP540, AEP655
Environmental Endocrinology	AEP541–AEP542
General Endocrinology	AEP543–AEP559
Pituitary and Neuroendocrinology	AEP560–AEP777
Reproductive and Developmental Endocrinology	AEP778–AEP856
Thyroid	AEP857–AEP1000
Hot topics (including COVID-19)	AEP1001–AEP1110

EPOSTER PRESENTATIONS

Adrenal and Cardiovascular Endocrinology	EP1–EP58
Bone and Calcium	EP59–EP123
Diabetes, Obesity, Metabolism and Nutrition	EP124–EP265
Endocrine-related Cancer	EP266–EP270
Environmental Endocrinology	EP271
General Endocrinology	EP272–EP279
Pituitary and Neuroendocrinology	EP280–EP373
Reproductive and Developmental Endocrinology	EP374–EP410
Thyroid	EP411–EP532
Hot topics (including COVID-19)	EP533–EP589

AUTHOR INDEX

Therefore, we conclude that EMT occurs in some somatotropinomas, but it does not seem to explain their response to SRL in this subset of tumors. However, in the rest of somatotropinoma *SNAIL* and *RORC* may predict the response to SRL treatment.

DOI: 10.1530/endoabs.70.AEP729

AEP730

Global methylation-demethylation status in pituitary neuroendocrine tumors as potential therapeutic target

Borbála Szabó¹, Kinga Németh², Katalin Mészáros^{2,3}, Nikolette Szücs¹, Sándor Cziráki⁴, Lilla Reiniger⁵, Attila Patócs^{2,3,6} & Henriett Butz^{2,3,6}

¹Semmelweis University, 2nd Department of Internal Medicine, Faculty of Medicine, Budapest, Hungary; ²Semmelweis University, Momentum Hereditary Endocrine Tumors Research Group, Budapest, Hungary;

³Semmelweis University, National Bionics Program, Budapest, Hungary;

⁴National Institute of Clinical Neurosciences, Budapest, Hungary;

⁵Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary; ⁶Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

Background

The altered DNA methylation of certain genes in Pituitary Neuroendocrine Tumors (PitNETs) are well known. However little information is available regarding global methylation changes and the process of demethylation in these tumors. In addition, influencing global methylation-demethylation could be a potential new therapeutic option especially in clinically non-functional PitNETs.

Material and methods

Overall, 44 fresh frozen pituitary adenoma tissues (29 gonadotroph, 12 somatotroph, 3 corticotroph) were collected and characterized according to the 2017 WHO classification. Decitabine was used to alter global methylation-demethylation status on *in vitro* GH3 and RC-4B/B cell lines. In tissue samples 5-hydroxymethylcytosine (5 hmC), UHRF1-2 protein and Ki-67 were assessed by immunohistochemistry; gene expression of DNA Methyltransferase (DNMT1), methyl-cytosine dioxygenases (TET1-3) and ubiquitin-like with PHD and ring finger domain (UHRF1-2) were investigated by RT-qPCR. 5-methylcytosine (5 mC) and 5 hmC level were determined by HPLC-MS/MS method.

Results

Decitabine decreased 5-methylcytosine (5 mC) and increased 5 hmC levels *in vitro* in both pituitary cell lines. Parallel, cell proliferation and viability were decreased significantly. UHRF1-2 were also altered upon decitabine treatment *in vitro*. Interestingly, in PitNET tissue samples 5 hmC was gradually decreased in samples with higher Ki-67 index. In samples with different histology UHRF2 showed different expression, while UHRF1 showed gradual increase in adenoma samples with higher Ki-67 index. Additionally, UHRF2 positively correlated with 5 hmC level in pitNET tissues and both UHRF1 and UHRF2 showed significant positive correlation with DNMT1 and TET1-3 expression.

Conclusion

Our results showed that methylation-demethylation process (5 hmC, DNMT1, TET1-3 and UHRF1-2) is closely linked to proliferative behaviour of PitNETs. Altering global 5 mC and 5 hmC level can be a potential, new therapeutic target in therapy resistant pituitary tumors.

Grants and financial support

This work has been funded by the National Program of Bionics (Program Medical Bionics lead by Attila Patócs) and Semmelweis Innovation Fund (STIA_19) to Henriett Butz. Henriett Butz is a recipient of Bolyai Research Fellowship of Hungarian Academy of Sciences and ÚNKP-18-4-SE-8 New National Excellence Program of The Ministry of Human Capacities.

DOI: 10.1530/endoabs.70.AEP730

AEP731

The expression of oxytocin receptor (OXTR) in metastatic pancreatic neuroendocrine tumors (PNETs)

Darko Katalinic¹, Stephan Bildat², Elke Kattner², Lilly Soerensen³, Ivan Aleric¹ & Aleksandar Vcev¹

¹Faculty of Dental Medicine and Health and Faculty of Medicine, Josip Juraj Strossmayer University of Osijek; ²Herford Teaching Hospital;

³Department of Cancer Medicine

Introduction

Pancreatic neuroendocrine tumors (PNETs) are rare malignant neoplasms which incidence is continually increasing. They are characterized by diverse biological behaviour and impact on the patients' prognosis, ranging from clinically indolent to very aggressive. Oxytocin receptor (OXTR) is a member of the family of G-protein receptors and is present on the cell-surface of the gastrointestinal organs. Unfortunately, the impact of OXTR signaling on the development of PNETs and its underlying molecular mechanisms involved in gastrointestinal oncogenesis remains insufficiently researched. The aim of our study was to assess the expression of OXTR in a group of patients diagnosed with metastatic PNETs.

Material and methods

Metastatic PNETs (liver metastases) specimens ($n=24$) matched control (normal) tissue were surgically collected and mRNA expression was determined by Real-time polymerase chain reaction (Real-time-PCR). OXTR expression for tumor and control tissue was additionally analysed by immunohistochemistry.

Results

Compared to normal tissue, the OXTR showed significant overexpression in metastatic PNETs. Moreover, significant overexpression of OXTR in tumor tissue was confirmed by immunohistochemistry.

Conclusion

Our findings highlight the possibility of making OXTR a promising novel molecular target for imaging and different therapeutic approach in patients diagnosed with metastatic PNETs.

DOI: 10.1530/endoabs.70.AEP731

AEP732

Metastatic insulinoma managed with lutetium (177Lu) and somatostatin analog

Mehmet Sözen, Zeynep Canturk, Berrin Cetinarslan, Alev Selek, Emre Gezer

Kocaeli University, Endocrinology and Metabolism, Kocaeli, Turkey

Background

Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas dimension (> 2 cm), CK19 status, tumour staging and grading (Ki67 $> 2\%$), and age of onset (> 50 years) can be considered elements of suspect.

Case presentation

We report a case of malignant insulinoma in a 80 year old woman presenting symptoms compatible with hypoglycemia. Low blood glucose levels (< 40 mg/dl) were documented during of these episodes. Symptoms regressed with food intake and intravenous glucose administration. No abnormality was detected in the biochemical evaluation. Prolong fasting test was performed, and the patient underwent symptomatic hypoglycemia at the 5th hour. Plasma glucose level was 39 mg/dl, insulin level 36.4 uIU/mL and C-peptide 9.28 ng/mL. Glucagon response was measured 10 min. intervals, 85 mg/dl, 95 mg/dl and 113 mg/dl respectively. These results were suggestive of endogenous hyperinsulinemia. Magnetic resonance imaging revealed an invasive mass in the pancreatic tail location $\sim 63 \times 40$ mm in size and multiple metastatic nodules in the liver. Ga-68 DOTATATE PET-CT, which showed a lesion located in the pancreatic tail location and multiple metastatic lesion in the liver, with a high somatostatin receptor density. True-cut biopsy made from liver lesions revealed the insulinoma tumour metastasis. Synaptophysin, pancytokeratin and chromogranin were positive. The histopathological diagnosis was suggestive of a neuroendocrine, grade-2 tumour (mitotic rate 1/10 HPF, Ki-67 proliferative index 15%). Lanreotide 120 mg IM was started an every 28 days basis. The patient received 2 infusions of radiolabeled somatostatin analog lutetium (177Lu) 8 weeks apart and denied any hypoglycemia. After the second administration of the lutetium, Ga-68 DOTATATE PET-CT had shown objective metabolic and radiologic response to treatment. Lutetium treatment was given as 8 cycles. Treatment of the patient with metabolic and radiological responses continues with lanreotide 90 mg/every 28 days.

Conclusions

We report a case of metastatic insulinoma treatment with somatostatin analog and Lutetium. Due to previous glycemic control reports and objective responses in unresectable cases, we decided to use Lutetium together with lanreotide. The patient's hypoglycaemia improved immediately after treatment. Unresectable metastatic insulinomas may present as a major therapeutic challenge for the physician. Treatment with lanreotide and Lutetium